Treatment of fatigue syndrome with cholinesterase inhibitors

Details Treatment of fatigue syndrome with cholinesterase inhibitors Treatment of fatigue syndrome with cholinesterase inhibitors

A - Human Necessities

61

K

A61K 31/55 (2006.01) A61K 31/13 (2006.01) A61K 31/27 (2006.01) A61K 31/325 (2006.01) A61K 31/365 (2006.01) A61K 31/40 (2006.01) A61K 31/405 (2006.01) A61K 31/44 (2006.01) A61K 31/47 (2006.01) A61K 31/66 (2006.01)

Patent

CA 2108880

2108880 9220327 PCTABS00017 The use of a pharmaceutically acceptable cholinesterase inhibitor or a prodrug therefor for the treatment of fatigue syndromes, including Chronic Fatigue Syndrome, Post-infectious Fatigue Syndromes, fatigue syndromes associated with human immunodeficiency virus (HIV) infection or with preeclampsia. The acetyl cholinesterase is preferably one that acts substantially selectively at nicotinic receptor sites, and which has selectivity for acetyl cholinesterase opposed to butyryl cholinesterase, e.g. galanthamine or a galanthamine derivative.

Affiliated with

Also associated with

Rating

Treatment of fatigue syndrome with cholinesterase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of fatigue syndrome with cholinesterase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of fatigue syndrome with cholinesterase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1688812